



Express Mail Certificate No.: EV 682 430 371 US Date: November 22, 2006

Docket No.: CDJ-166CPRCE
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yashwant M. Deo *et al.*

Application No.: 10/035637

Confirmation No.: 4452

Filed: November 7, 2001

Art Unit: 1644

For: HUMAN MONOCLONAL ANTIBODIES TO
DENDRITIC CELLS

Examiner: G. R. Ewoldt

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement. Applicant has not submitted a copy of the cited U.S. patents in accordance with 37 CFR 1.98(a)(2)(ii).

This Information Disclosure Statement is filed more than three months after the U.S. filing date, after the mailing date of the first Office Action on the merits, before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

11/22/06
02 Fr 1836
00000001 120080
10035637


I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-166CPRCE.

Dated: November 22, 2006

JMD/JRG/mch/ncm

Respectfully submitted,

By 
Jeanne M. DiGiorgio
Registration No.: 41,710
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number:	10/035,637-Conf. #4452
Filing Date	November 7, 2001
First Named Inventor:	Yashwant M. DEO
Art Unit	1644
Examiner Name	G. R. Ewoldt
Attorney Docket Number	CDJ-166CPRCE

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-5,869,057	02-09-1999	Rock	
	A2*	US-6,080,409	06-27-2000	Laus et al.	
	A3*	US-6,277,959	08-21-2001	Valladeau et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		
	B2	WO-93/04187-A1	03-04-1993	Medical Research Council		
	B3	WO-96/23882-A1	08-08-1996	The Rockefeller University		
	B4	WO-97/45449-A1	12-04-1997	Hart, Derek et al.		
	B5	WO-99/02562-A1	01-21-1999	Schering Corporation		
	B6	WO-99/16455-A1	04-08-1999	The Austin Research Institute		
	B7	WO-99/24554-A2	05-20-1999	University of Pittsburgh		
	B8	WO-99/47673-A2	09-23-1999	Schering Corporation		
	B9	WO-99/58678-A2	11-18-1999	Micromet GmbH		
	B10	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		
	B11	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		
	B12	WO-00/18803-A2	04-06-2000	Schering Corporation		
	B13	WO-01/85798-A2	11-15-2001	Medarex, Inc.		
	B14	WO-03/040169-A2	05-15-2003	Medarex, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Berlyn, K. et al, "Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes," <i>Clin. Immunol.</i> , Vol. 101(3):276-83 (2001)	
	C2	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	C3	Frleta, Davor et al, "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)	
	C4	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/035,637-Conf. #4452
				Filing Date	November 7, 2001
				First Named Inventor	Yashwant M. DEO
				Art Unit	1644
				Examiner Name	G. R. Ewoldt
Sheet	2	of	2	Attorney Docket Number	CDJ-166CPRCE

C5	He, Li-Zhen et al., "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen Human Chorionic Gonadotropin β ," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)	
C6	He, Lizhen et al., "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCG/3 Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, pg. 167 (2003)	
C7	Kawakami, Y. et al., "The use of melanosomal proteins in the immunotherapy of melanoma," <i>J. Immunother.</i> , Vol. 21(4):237-246 (1998)	
C8	Potter, Kathleen N. et al., "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
C9	Ramakrishna, Venky et al., "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)	
C10	Ramakrishna, Venky et al., "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)	
C11	Rudikoff, Stuart et al., "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)	
C12	Tempest, Philip R. et al., "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
C13	Tjoa, Benjamin A. et al., "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
C14	Wang, Hui et al., "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	
C15	Partial European Search Report for Application No. 02778814.0, dated April 25, 2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--